Relationship between high-dose statin therapy and risk of osteoporosis confirmed in mouse models

Using several million medical records, a research group from MedUni Vienna and the Complexity Science Hub (CSH) showed that there was a correlation between the dosage of statins and the diagnosis of osteoporosis as early as 2019. This finding has now been confirmed in a preclinical study, which was recently published in the journal Biomedicine and Pharmacotherapy. Statins are among the most frequently prescribed drugs. The higher the dosage, the greater the risk of osteoporosis: this was the key finding from the previous Big Data analysis in 2019. This finding has now been confirmed in preclinical studies. "This is the first time that the link between a high dose of statins and osteoporosis has been demonstrated in an animal model," says Alexandra Kautzky-Willer and Michael Leutner from the University Internal Medicine III Department, Division of Endocrinology and Metabolism, at MedUni Vienna. In 2019, in a Big Data analysis the research team found that high doses of statins were associated with an increased risk of bone loss (osteoporosis), whereas low doses were actually associated with a lower risk of osteoporosis.